Viral Diseases

A single patient, confirmed influenza A two and a half days into her illness. The disagreement isn't about whether an antiviral works in general — it's about whether either drug still means anything once the trials that proved it stop covering the patient in front of you.

A single patient, worsening on hospital day five despite oseltamivir, with genotypic confirmation that the virus itself has already answered the question everyone is still debating. The disagreement is about what to do with a drug that's still in his system doing nothing.

A single patient, five years post-kidney-transplant, newly diagnosed with COVID-19 on the one drug with the strongest efficacy data and the one interaction that could cost him his graft. The disagreement is whether managing that interaction is safer than avoiding it.

A single patient, four days past finishing a full course of nirmatrelvir/ritonavir and feeling worse than she did on day two. The disagreement is whether rebound is a treatment failure asking for more drug, or a known phenomenon the drug never promised to prevent.

A single patient, high-risk for COVID-19 progression, at an eGFR both antivirals now carry labeled dosing for. The disagreement is what to do when two options are equally labeled and equally unstudied for efficacy at her kidney function.

A single patient, two weeks post-kidney-transplant and at the highest-risk CMV serostatus mismatch there is. The disagreement isn't whether he needs protection from CMV disease — it's whether watching for it or blocking it outright is the safer strategy for his marrow, not just his graft.

A single patient, on his third week of valganciclovir with a rising, not falling, CMV viral load and a genotype that explains why. The disagreement is between a drug proven to clear resistant virus and a drug that avoids the exact organ injury he can least afford right now.

A single patient, five days into a shingles rash that has spread to the tip of his nose. The disagreement is whether the textbook 72-hour antiviral window is a real biological cutoff or a convenience threshold that a still-active, sight-threatening rash overrides.

A single patient, 79 years old, with severe acute shingles pain and every risk factor for the nerve pain that can outlast the rash by months. The disagreement is whether stretching the antiviral course beyond the standard week actually lowers that risk, or just extends a drug that's already done its job.

A single patient, eight days post-transplant and still profoundly neutropenic, with RSV that has moved from her nose into her lungs. The disagreement is whether a resource-intensive, poorly randomized-evidenced therapy is worth its own real toxicity in the window where she's most likely to benefit from it.

A single patient, living with poorly-controlled HIV, in severe pain from mpox proctitis that supportive care alone isn't touching. The disagreement is what is left of a drug after two negative randomized trials, neither of which put a patient like him in a comparative arm.

A single patient, bitten by a bat in her attic, with a rabies vaccination history from years before her current B-cell-depleting therapy. The disagreement is whether her prior vaccine record still means what it would in someone whose immune system hasn't since been deliberately suppressed.

A single patient, a child three weeks past a cord-blood transplant, with adenovirus now detectable in his blood and his liver enzymes climbing. The disagreement is between the drug with the longer track record and the one built specifically to avoid its most dangerous side effect.

A single patient, finishing her last cycle of rituximab-based chemotherapy for lymphoma, hepatitis-B core-antibody positive but surface-antigen negative. The disagreement isn't whether she needed prophylaxis — it's when it's actually safe to stop it.

A single patient, chronic hepatitis D superinfecting his hepatitis B, with early cirrhosis on biopsy. The disagreement is whether starting a genuinely new drug now, likely for the rest of his life, is worth committing to before its own long-term relapse-after-stopping data have matured.

A single patient, hepatitis C positive and stable on amiodarone for atrial fibrillation nobody wants to destabilize. The disagreement is which direct-acting antiviral regimen actually avoids trading one real risk for another.

A single patient, five weeks post-transplant, with a perianal ulcer that has only grown despite appropriately-dosed acyclovir. The disagreement is between the drug with the stronger track record and the one that spares him thrice-daily infusions he's already struggling to tolerate.

A single patient, 34 weeks pregnant with her first-ever genital herpes outbreak. The disagreement isn't whether to start suppressive therapy — it's whether antiviral suppression alone can do enough to make the delivery-mode decision less urgent than it looks.